Literature DB >> 3122314

Responsiveness in diffuse versus local cutaneous leishmaniasis is due to parasite differences.

H Akuffo1, E Schurr, G Andersson, T Yamaneberhan, S Britton.   

Abstract

Leishmania aethiopica infection results in two main clinical entities, diffuse disease (DCL) and localized ulcers (LCL). The lack of reactivity to leishmanial antigens has been attributed, among other things, to some inherent immunological defect of the host or considered as a consequence of the initial site of infection. Properties unique to the infecting parasite have been said to contribute little if anything to the differences between DCL and LCL found in the same areas of Ethiopia. Data are given to show that infected individuals respond by higher production of IL-2 to antigens from LCL isolates (lcl antigen), than to antigens derived from DCL isolates (dcl antigen). Furthermore, dcl antigen induced less gamma interferon from lymphocytes of all individuals tested than did lcl antigen. Lymphocytic proliferation of cells from control individuals working in the endemic area was higher in response to lcl isolates than to dcl isolates. These findings suggest that some differences in the parasites may contribute to the clinical outcome of infection with L. aethiopica.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3122314     DOI: 10.1111/j.1365-3083.1987.tb02308.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  9 in total

1.  Systemic FasL and TRAIL neutralisation reduce leishmaniasis induced skin ulceration.

Authors:  Geremew Tasew; Susanne Nylén; Thorsten Lieke; Befekadu Lemu; Hailu Meless; Nicolas Ruffin; Dawit Wolday; Abraham Asseffa; Hideo Yagita; Sven Britton; Hannah Akuffo; Francesca Chiodi; Liv Eidsmo
Journal:  PLoS Negl Trop Dis       Date:  2010-10-12

2.  Immune reactivity to fractionated Leishmania aethiopica antigens during active human infection.

Authors:  T Laskay; H G Mariam; T Y Berhane; T E Fehniger; R Kiessling
Journal:  J Clin Microbiol       Date:  1991-04       Impact factor: 5.948

3.  Isolation and characterization of recombinant antigens from Leishmania aethiopica that react with human antibodies.

Authors:  A Osland; D Beyene; S Ashenafi; A Beetsma
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

Review 4.  The relationship between leishmaniasis and AIDS: the second 10 years.

Authors:  Jorge Alvar; Pilar Aparicio; Abraham Aseffa; Margriet Den Boer; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Rachel Ter Horst; Rogelio López-Vélez; Javier Moreno
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

5.  Contribution of non-Leishmania-specific immunity to resistance to Leishmania infection in humans.

Authors:  H O Akuffo; S F Britton
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

6.  Natural and acquired resistance to Leishmania: cellular activation by Leishmania aethiopica of mononuclear cells from unexposed individuals is through the stimulation of natural killer (NK) cells.

Authors:  H Akuffo; K Maasho; R Howe
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

7.  FasL and TRAIL signaling in the skin during cutaneous leishmaniasis - implications for tissue immunopathology and infectious control.

Authors:  Bence Rethi; Liv Eidsmo
Journal:  Front Immunol       Date:  2012-06-19       Impact factor: 7.561

8.  Differential effects of antigens from L. braziliensis isolates from disseminated and cutaneous leishmaniasis on in vitro cytokine production.

Authors:  Paulo T G Leopoldo; Paulo R L Machado; Roque P Almeida; Albert Schriefer; Angela Giudice; Amélia Ribeiro de Jesus; John L Ho; Luiz Henrique Guimarães; Olívia Bacellar; Edgar M Carvalho
Journal:  BMC Infect Dis       Date:  2006-04-25       Impact factor: 3.090

9.  Exposure of phosphatidylserine on Leishmania amazonensis isolates is associated with diffuse cutaneous leishmaniasis and parasite infectivity.

Authors:  Jaqueline França-Costa; João Luiz Mendes Wanderley; Poliana Deolindo; Jessica B Zarattini; Jackson Costa; Lynn Soong; Marcello André Barcinski; Aldina Barral; Valeria M Borges
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.